Zacks Research Has Pessimistic Outlook of AXSM Q1 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Research analysts at Zacks Research cut their Q1 2027 EPS estimates for shares of Axsome Therapeutics in a note issued to investors on Friday, December 26th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.59 for the quarter, down from their prior forecast of $0.69. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The business had revenue of $170.99 million during the quarter, compared to the consensus estimate of $162.96 million. The company’s revenue was up 63.2% compared to the same quarter last year.

A number of other analysts have also commented on AXSM. Royal Bank Of Canada lifted their price objective on Axsome Therapeutics from $189.00 to $198.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 4th. Guggenheim lifted their price objective on Axsome Therapeutics from $200.00 to $205.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Morgan Stanley increased their target price on Axsome Therapeutics from $194.00 to $196.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Wednesday, October 8th. Finally, B. Riley initiated coverage on shares of Axsome Therapeutics in a report on Wednesday, October 1st. They issued a “buy” rating and a $179.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Axsome Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $179.88.

Axsome Therapeutics Price Performance

NASDAQ:AXSM opened at $152.05 on Monday. The company’s 50-day moving average price is $143.40 and its two-hundred day moving average price is $123.48. The company has a quick ratio of 1.50, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. Axsome Therapeutics has a 12 month low of $75.56 and a 12 month high of $158.56. The firm has a market cap of $7.66 billion, a PE ratio of -32.56 and a beta of 0.47.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Swiss National Bank lifted its position in shares of Axsome Therapeutics by 6.9% during the second quarter. Swiss National Bank now owns 65,200 shares of the company’s stock valued at $6,806,000 after purchasing an additional 4,200 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Axsome Therapeutics by 55.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 203,632 shares of the company’s stock worth $21,257,000 after buying an additional 72,609 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Axsome Therapeutics by 154.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 4,424 shares of the company’s stock worth $462,000 after buying an additional 2,686 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Axsome Therapeutics by 62.9% in the third quarter. Assenagon Asset Management S.A. now owns 294,771 shares of the company’s stock valued at $35,800,000 after acquiring an additional 113,811 shares in the last quarter. Finally, KLP Kapitalforvaltning AS grew its holdings in shares of Axsome Therapeutics by 36.6% in the second quarter. KLP Kapitalforvaltning AS now owns 11,200 shares of the company’s stock valued at $1,169,000 after acquiring an additional 3,000 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Insider Activity at Axsome Therapeutics

In related news, CEO Herriot Tabuteau sold 91,705 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $132.34, for a total transaction of $12,136,239.70. Following the transaction, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $956,685.86. This trade represents a 92.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 289,296 shares of company stock valued at $38,882,311 over the last 90 days. 22.40% of the stock is currently owned by corporate insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.